{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:41:29Z","timestamp":1789749689147,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T00:00:00Z","timestamp":1572048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T00:00:00Z","timestamp":1572048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lexicon","award":["LX1017C"],"award-info":[{"award-number":["LX1017C"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Carcinoid syndrome is associated with a reduced quality of life that can be attributed to symptoms such as diarrhea and fatigue as well as social and financial issues. This study was conducted to psychometrically assess meaningful change in bowel movement frequency among carcinoid syndrome patients using data from the TELESTAR clinical study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An anchor-based approach for deriving meaningful change thresholds consisted of mapping change from baseline bowel movement frequency to other patient-reported assessments of change. These included the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core Questionnaire (QLQ-C30) Diarrhea Symptom responders, the EORTC Gastrointestinal NET questionnaire (GI.NET21) GI Symptom responders, and reported adequate relief at Week 12 (\u2265 10-point score decrease from Day 1 to Week 12). Parameters included within-group mean change from baseline to Week 12, t-tests of the change (Wilcoxon rank sum for adequate relief), and effect size.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 135 carcinoid syndrome patients with a mean baseline frequency of 5.7 bowel movements a day. A distribution-based method yielded meaningful change estimates of 0.62 bowel movements a day for overall frequency and 0.83 bowel movements a day at Week 12. Anchor-based analysis indicated a large effect size among patients who reported adequate relief at Week 12 (\u2212\u20091.58;<jats:italic>n<\/jats:italic>\u2009=\u200918;<jats:italic>P<\/jats:italic>\u2009=\u20090.014), the QLQ-C30 Diarrhea domain responders (\u2212\u20091.24;<jats:italic>n<\/jats:italic>\u2009=\u200940;<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and the GI.NET21 GI Symptoms Domain responders (\u2212\u20091.49;<jats:italic>n<\/jats:italic>\u2009=\u200925;<jats:italic>P<\/jats:italic>\u2009=\u20090.005). Exit interview data for meaningful change yielded effect size estimates of \u2212\u20091.57 for overall change during the Double-blind Treatment Period and\u2009\u2212\u20091.97 for change between Baseline and Week 12.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Meaningful change derivation is critical to interpret patient outcomes for evaluating treatment efficacy. In this study, carcinoid syndrome patients experienced clinically meaningful reductions in bowel movement frequency of \u226530% over 12\u2009weeks with telotristat ethyl treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01677910\">NCT01677910<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s41687-019-0153-y","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T10:02:39Z","timestamp":1572084159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome"],"prefix":"10.1186","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-1549","authenticated-orcid":false,"given":"Stacie","family":"Hudgens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ramage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bergsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn","family":"Caplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"\u00d6berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon","family":"Gable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi Melissa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Lapuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,26]]},"reference":[{"key":"153_CR1","first-page":"429","volume":"74","author":"R Robertson","year":"2006","unstructured":"Robertson, R., Geiger, W., & Davis, N. (2006). Carcinoid tumors. American Family Physician, 74, 429\u2013434.","journal-title":"American Family Physician"},{"key":"153_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","volume":"41","author":"J Beaumont","year":"2012","unstructured":"Beaumont, J., Cella, D., Phan, A., Choi, S., Liu, Z., & Yao, J. (2012). Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas, 41, 461\u2013466.","journal-title":"Pancreas"},{"key":"153_CR3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.33590\/emjoncol\/10313153","volume":"3","author":"S Kaupp-Roberts","year":"2015","unstructured":"Kaupp-Roberts, S., Srirajaskanthan, R., & Ramage, J. (2015). Symptoms and quality of life in gastroenteropancreatic neuroendocrine tumours. EMJ Oncology, 3, 34\u201340.","journal-title":"EMJ Oncology"},{"key":"153_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1677\/erc.0.0100483","volume":"10","author":"J Ramage","year":"2003","unstructured":"Ramage, J., & Davies, A. (2003). Measurement of quality of life in carcinoid\/neuroendocrine tumours. Endocrine-Related Cancer, 10, 483\u2013486.","journal-title":"Endocrine-Related Cancer"},{"key":"153_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/bjc.2012.560","volume":"108","author":"G Yadegarfar","year":"2013","unstructured":"Yadegarfar, G., Friend, L., Jones, L., Plum, L., Ardill, J., Taal, B., Larsson, G., Jeziorski, K., Kwekkeboom, D., & Ramage, J. (2013). Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. British Journal of Cancer, 108, 301\u2013310.","journal-title":"British Journal of Cancer"},{"key":"153_CR6","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncr.11105","volume":"97","author":"I Modlin","year":"2003","unstructured":"Modlin, I., Lye, K., & Kidd, M. (2003). A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 97, 934\u2013959.","journal-title":"Cancer"},{"key":"153_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1634\/theoncologist.10-2-123","volume":"10","author":"J Zuetenhorst","year":"2005","unstructured":"Zuetenhorst, J., & Taal, B. (2005). Metastatic carcinoid tumors: A clinical review. Oncologist, 10, 123\u2013131.","journal-title":"Oncologist"},{"key":"153_CR8","unstructured":"(2017) National Cancer Institute. Gastrointestinal carcinoid tumors treatment (PDQ) - health professional version. Available at: https:\/\/www.cancer.gov\/types\/gi-carcinoid-tumors\/hp\/gi-carcinoid-treatment-pdq . Accessed 15 June 2018."},{"key":"153_CR9","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.amjcard.2010.12.025","volume":"107","author":"S Bhattacharyya","year":"2011","unstructured":"Bhattacharyya, S., Toumpaakis, C., Chilkunda, D., Caplin, M., & Davar, J. (2011). Risk factors for the development and progression of carcinoid heart disease. The American Journal of Cardiology, 107, 1221\u20131226.","journal-title":"The American Journal of Cardiology"},{"key":"153_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa021451","volume":"348","author":"J Moller","year":"2003","unstructured":"Moller, J., Connolly, H., Rubin, J., Seward, J., Modesto, K., & Pellikka, P. (2003). Factors associated with progression of carcinoid heart disease. The New England Journal of Medicine, 348, 1005\u20131015.","journal-title":"The New England Journal of Medicine"},{"key":"153_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrendo.2009.51","volume":"5","author":"M Druce","year":"2009","unstructured":"Druce, M., Rockall, A., & Grossman, A. (2009). Fibrosis and carcinoid syndrome: From causation to future therapy. Nature Reviews. Endocrinology, 5, 276\u2013283.","journal-title":"Nature Reviews. Endocrinology"},{"key":"153_CR12","unstructured":"(2017) National Institutes of Health. ClinicalTrials.gov website. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01677910 . Accessed 15 June 2018."},{"key":"153_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","volume":"35","author":"M Kulke","year":"2017","unstructured":"Kulke, M., Horsch, D., Caplin, M., Anthony, L., Bergsland, E., Oberg, K., Welin, S., Warner, R., Lombard-Bohas, C., Kunz, P., Grande, E., Valle, J., Fleming, D., Lapuerta, P., Banks, P., Jackson, S., Zambrowicz, B., Sands, A., & Pavel, M. (2017). Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. Journal of Clinical Oncology, 35, 14\u201323.","journal-title":"Journal of Clinical Oncology"},{"key":"153_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"N Aaronson","year":"1993","unstructured":"Aaronson, N., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N., Filiberti, A., Flechtner, H., Fleishman, S., & de Haes, J. (1993). The European Organization for Research and Treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365\u2013376.","journal-title":"Journal of the National Cancer Institute"},{"key":"153_CR15","unstructured":"(2017) EORTC Quality of Life. EORTC QLQ-GI.NET21. Available at: http:\/\/groups.eortc.be\/qol\/sites\/default\/files\/img\/slider\/specimen_gi.net21_english.pdf . Accessed 15 June 2018."},{"issue":"11","key":"153_CR16","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.clinthera.2017.09.013","volume":"39","author":"Lowell Anthony","year":"2017","unstructured":"Anthony, L., Ervin, C., Lapuerta, P., Kulke, M., Kunz, P., Bergsland, E., Horsch, D., Metz, D., Pasieka, J., Pavlakis, N., Pavel, M., Caplin, M., Oberg, K., Ramage, J., Evans, E., Yang, Q., Jackson, S., Arnold, K., Law, L., & DiBenedetti, D. (2017). Understanding the patient experience with carcinoid syndrome: Exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clinical Therapeutics, (17), 30987\u201330986. https:\/\/doi.org\/10.1016\/j.clinthera.2017.09.013 [Epub ahead of print].","journal-title":"Clinical Therapeutics"},{"key":"153_CR17","unstructured":"(2013). SAS version 9 [computer software]. Cary: SAS Institute Inc."},{"key":"153_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki, D., Hays, R., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61, 102\u2013109.","journal-title":"Journal of Clinical Epidemiology"},{"key":"153_CR19","doi-asserted-by":"crossref","unstructured":"Litwin, M. S. (1995). How to measure survey reliability and validity. Thousand Oaks: Sage Publications.","DOI":"10.4135\/9781483348957"},{"key":"153_CR20","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1097\/00005650-198903001-00015","volume":"27","author":"L Kazis","year":"1989","unstructured":"Kazis, L., Anderson, J., & Meenan, R. (1989). Effect sizes for interpreting changes in health status. Medical Care, 27, S178\u2013S189.","journal-title":"Medical Care"},{"key":"153_CR21","unstructured":"Cohen J (1977) Statistical power analysis for the behavioral sciences (rev. Lawrence Erlbaum Associates, Inc)."},{"issue":"1","key":"153_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","volume":"27","author":"Cheryl D. Coon","year":"2017","unstructured":"Coon, C., & Cook, K. (2017). Moving from significance to real-world meaning: Methods for interpreting change in clinical outcome assessment scores. Quality of Life Research. https:\/\/doi.org\/10.1007\/s11136-017-1616-3 [Epub ahead of print].","journal-title":"Quality of Life Research"},{"key":"153_CR23","unstructured":"(2017) Xermelo (telotristat ethyl) prescribing information. United States Food and Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208794s000lbl.pdf . Accessed 10 July 2018."}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-019-0153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s41687-019-0153-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-019-0153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T04:50:26Z","timestamp":1695358226000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-019-0153-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,26]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["153"],"URL":"https:\/\/doi.org\/10.1186\/s41687-019-0153-y","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,26]]},"assertion":[{"value":"18 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This observational study included no administration of any therapeutic or prophylactic agent. There were no anticipated physical risks or direct benefits to patients participating in the study, although patients may become uncomfortable or emotional discussing their experiences with carcinoid syndrome symptoms. As such, participation was completely voluntary and participants could withdraw at any time and still receive (as applicable) the full exit study incentive. Participation in the exit interview was not a requirement for TELESTAR clinical trial participation (e.g., should a patient decide not to participate in an exit interview, they could still continue in any remaining clinical trial activities [e.g., open-label treatment period]). An incentive for participation in the exit interview substudy was provided, if approved by each participating clinical site\u2019s local ethics review board, to compensate patients for their time. The amount and payment methods was reviewed and approved by each ethics committee to ensure that payments (if allowed) were commensurate with the time needed to participate in the interview and were not coercive.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S. Hudgens and J. Gable are employed by Clinical Outcomes Solutions, the organization contracted by Lexicon to analyze the data and develop this manuscript. These authors have no additional financial relationships or otherwise to declare. M. Kulke has received consulting fees from Lexicon, Novartis, and Ipsen outside the submitted work. E. Bergsland is an uncompensated adviser for Lexicon Pharmaceuticals, Inc., and Ipsen. L. Anthony has received grants from Lexicon Pharmaceuticals Inc. M. Caplin has received compensation from Lexicon Pharmaceuticals Inc for participation on an advisory board. K. \u00d6berg has received honoraria and speakers\u2019 bureau fees from Novartis and Ipsen. M. Pavel has received consulting fees from Lexicon Pharmaceuticals Inc, Novartis, and Ipsen. P. Banks, Q.M. Yang, and P. Lapuerta are all currently employees of Lexicon Pharmaceuticals Inc and own stock. The authors have declared that they have no other competing interests regarding the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}